Cronos Group (CRON) Q4 2025 Earnings, Here's a Snapshot

Cronos Group Inc. (NASDAQ:CRON) is one of the Low Risk Penny Stocks to Buy Now. On February 26, Cronos Group Inc. (NASDAQ:CRON) reported its fiscal Q4 2025 earnings. The company posted $44.53 million in quarterly revenue, up 47.1% year-over-year and ahead of expectations by $5.78 million.

Management attributed revenue growth to be driven by strong demand for its leading brands, the completion of Cronos GrowCo expansion, and increased contribution from international markets. Notably, gross profit for the quarter came in at $16.2 million, reflecting an increase of $5.4 million year-over-year. Management noted the increased profitability to be led by a higher average selling price due to a better sales mix from Israel and other international countries.

Looking ahead, Cronos Group Inc. (NASDAQ:CRON) is positive about its acquisition of CanAdelaar, which will mark its entry into the European market.

Founded in 2012 and headquartered in Toronto, Cronos Group Inc. (NASDAQ:CRON) is a cannabinoid company that cultivates, produces, and markets cannabis products globally. It sells a range of products such as dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under its brands such as Spinach, Lord Jones, and PEACE NATURALS.

While we acknowledge the potential of CRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Follow Insider Monkey on Google News.